Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy

被引：0
作者：
Tauveron-Jalenques, Urbain [1 ]
Lambert, Juliette [2 ]
机构：
[1] CHU Clermont Ferrand, Serv Therapie Cellulaire & Dhematol Clin Adulte, F-63100 Clermont Ferrand, France
[2] Ctr hospitalier Versailles, Serv Dhematol, F-78150 Le Chesna Rocquencourt, France
来源：
BULLETIN DU CANCER | 2024年 / 111卷 / 05期
关键词：
Acute myeloid leukaemia; AML; Decitabine; Cedazuridine; Hypomethylating agent; Unfit;
D O I：
10.1016/j.bulcan.2024.01.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 436
页数：2
相关论文
共 50 条
  • [21] Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia
    Jiayu Huang
    Huihui Zhao
    Ming Hong
    Han Zhu
    Yu Zhu
    Yun Lian
    Shan Li
    Jianyong Li
    Sixuan Qian
    [J]. BMC Cancer, 18
  • [22] Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation
    Sweet, Kendra
    Cluzeau, Thomas
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (01) : 61 - 68
  • [23] A new option for remission induction in acute myeloid leukaemia
    Mueller-Tidow, Carsten
    Schlenk, Richard F.
    [J]. LANCET ONCOLOGY, 2018, 19 (02) : 156 - 157
  • [24] The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia
    Frisch, Avi
    Rowe, Jacob M.
    Ofran, Yishai
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (05) : 556 - 562
  • [25] Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy
    Kristensen, Daniel Tuyet
    Brondum, Rasmus Froberg
    orskov, Andreas Due
    Marcher, Claus Werenberg
    Schollkopf, Claudia
    Sorensen, Anne Louise Tolboll
    Severinsen, Marianne Tang
    Bogsted, Martin
    Roug, Anne Stidsholt
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 573 - 582
  • [26] Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia
    Park, Hyunkyung
    Youk, Jeonghwan
    Kim, Inho
    Yoon, Sung-Soo
    Park, Seonyang
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Koh, Youngil
    [J]. ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1777 - 1786
  • [27] Clinical efficacy of decitabine-containing induction chemotherapy in de novo non-elderly acute myeloid leukemia
    Zheng, Lu
    Huang, Lifang
    Hui, Yan
    Huang, Liang
    Li, Yi
    Shang, Zhen
    Wei, Jia
    Wang, Zhiqiong
    Mao, Xia
    Wang, Yin
    Xiao, Min
    Zhang, Donghua
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (06) : 1521 - 1528
  • [28] Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
    Johnston, DL
    Meshinchi, S
    Opheim, KE
    Pallavicini, MG
    Feusner, J
    Woods, WG
    Lange, BJ
    Radich, JP
    Bernstein, ID
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (03) : 431 - 435
  • [29] Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia
    Fleming, Shaun
    Ong, Doen Ming
    Jackson, Kathryn
    Avery, Sharon
    Mollee, Peter
    Marlton, Paula
    Kennedy, Glen
    Wei, Andrew H.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 328 - 330
  • [30] Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission
    Yao, Wen
    Chu, Xiandeng
    Fang, Xinchen
    Zhu, Xiaoyu
    Tang, Baolin
    Wan, Xiang
    Geng, Liangquan
    Tong, Juan
    Song, Kaidi
    Zhang, Xuhan
    Qiang, Ping
    Sun, Guangyu
    Liu, Huilan
    Sun, Zimin
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (06) : 1372 - 1381
12345